Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Short-term Investments (2018 - 2025)

Historic Short-term Investments for AC Immune (ACIU) over the last 8 years, with Q3 2025 value amounting to $100.9 million.

  • AC Immune's Short-term Investments rose 18663.16% to $100.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.9 million, marking a year-over-year increase of 18663.16%. This contributed to the annual value of $147.5 million for FY2024, which is 9946.71% down from last year.
  • According to the latest figures from Q3 2025, AC Immune's Short-term Investments is $100.9 million, which was up 18663.16% from $122.5 million recorded in Q2 2025.
  • In the past 5 years, AC Immune's Short-term Investments registered a high of $125.8 billion during Q4 2021, and its lowest value of -$116.5 million during Q3 2024.
  • Over the past 5 years, AC Immune's median Short-term Investments value was $94.5 million (recorded in 2022), while the average stood at $11.9 billion.
  • Within the past 5 years, the most significant YoY rise in AC Immune's Short-term Investments was 37899751.7% (2021), while the steepest drop was 41700.75% (2021).
  • Over the past 5 years, AC Immune's Short-term Investments (Quarter) stood at $125.8 billion in 2021, then tumbled by 99.92% to $94.5 million in 2022, then surged by 29204.54% to $27.7 billion in 2023, then plummeted by 99.47% to $147.5 million in 2024, then tumbled by 31.58% to $100.9 million in 2025.
  • Its last three reported values are $100.9 million in Q3 2025, $122.5 million for Q2 2025, and $139.8 million during Q1 2025.